A Phase II Study to Assess the Activity of PD-L1 Inhibition With Durvalumab (MEDI4736) After Chemo-Radiotherapy in Patients With Stage II-IV Microsatellite Stable (MSS) Rectal Cancer
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Durvalumab (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- 07 Sep 2017 Planned End Date changed from 1 Sep 2019 to 1 Dec 2019.
- 07 Sep 2017 Planned primary completion date changed from 1 Sep 2019 to 1 Dec 2019.
- 07 Sep 2017 Planned initiation date changed from 1 Jul 2017 to 1 Oct 2017.